Robotic surgery that makes sense.

Introducing the advantages of robotic technology with haptic feedback coupled with a breakthrough cost-effective platform. For use in general, gynecologic, urologic and thoracic surgical procedures.
Enhanced senses

**ENHANCED ERGONOMICS**
- Surgeon seated at cockpit
- Clutch to easily reposition hands
- Open cockpit for ease of patient side communication

**ENHANCED HAPTICS**
- Haptic force feedback on multiple degrees
- Force sensing of instrument fulcrum point
- Alerts surgeon if detecting excessive forces
- Awareness of forces on instrument even if outside field of view

**ENHANCED MOTION**
- Robotic precision with enhanced motion
- Stabilize and control multiple instruments
- Wristed instrument options

**ENHANCED VISION**
- Eye-sensing camera control
- 3DHD vision
- Move multiple instruments and camera simultaneously
A system that makes sense

**Sensible** Economics

- Fully reusable instrumentation
- Standard 5mm instrument diameter
- Utilize robotics at per procedure costs similar to traditional laparoscopy

**Sensible** Integration into Surgical Practice

- Minimal setup with no docking to patient
- Utilize existing trocars
- Operates with laparoscopic motion
- Multiquadrant with flexible positioning of arms
Senhance: Delivering Clinical Results
Active clinical sites throughout Europe.

Selected Papers

Published clinical data on 200+ patients suggest that Senhance Robotic Surgery (“ALF-X”) is safe and feasible for various benign and malignant conditions and in obese patients, with procedural costs similar to laparoscopy.

- Benchtop learning curve studies¹,²
- Case series on feasibility and safety profile for benign and malignant disease and in obese patients³-⁵
- Retrospective comparative vs. laparoscopy for early stage endometrial cancer⁶,⁷
- Cost analysis of robotic hysterectomy⁷

Authors noted:

- Short learning curve may be associated with system similarity to laparoscopy
- Short docking time (median 7 minutes in initial cases)
- Haptic feedback when applying traction and other forces on tissue
- 5mm instrumentation and haptic fulcrum may contribute to mitigating post-operative pain
- Potential for robotics with sustainable economics due to reusable instruments

For a full list of publications and to learn more, visit www.transenterix.com


Senhance (formerly "ALF-X") is CE marked according to MDD and is intended to be used for laparoscopic surgery in the abdomen and pelvis of adult human patients. The device is restricted to sale by or on the order of a physician. Senhance is not available for sale in the United States.

Senhance is a trademark of TransEnterix Surgical, Inc. ALF-X is a registered trademark of TransEnterix Italia Srl. Senhance was developed under a license of the European Commission Joint Research Centre.

BRO-001-0005-002

Distributed by
Lawmed Ltd.
Russell House, Molesey Road
Hersham, KT12 3PJ. United Kingdom

T: +44 (0)845 241 1510
F: +44 (0)845 241 1520
E: enquiries@lawmed.co.uk
www.lawmed.co.uk

ADVANCING SURGICAL POSSIBILITIES